The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Millennium; Progenics
Research Funding - Agensys (Inst); Bayer (Inst); Endocyte (Inst); Janssen Oncology (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - fujifilm
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Janssen; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Roche; Sanofi
 
Karim Fizazi
Consulting or Advisory Role - Bayer
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - AstraZeneca; Bayer; Ferring
Speakers' Bureau - Janssen
Research Funding - Karyopharm Therapeutics (Inst)
 
Daniel H. Shevrin
Speakers' Bureau - Astellas Pharma; Bayer
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Monica Seger
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Patents, Royalties, Other Intellectual Property - Late husband has several patents; I have received royalties (I)
 
Chengxing Lu
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva